Why Do Phase III Clinical Trials in Oncology Fail so Often?

被引:39
作者
Amiri-Kordestani, Laleh [1 ]
Fojo, Tito [1 ]
机构
[1] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
关键词
DRUG DEVELOPMENT; TARGETED AGENTS; STABLE DISEASE; END-POINT; CHEMOTHERAPY; SURVIVAL; CANCER; BENEFIT; DESIGNS;
D O I
10.1093/jnci/djs180
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:568 / 569
页数:2
相关论文
共 50 条
[21]   A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology [J].
Comets, Emmanuelle ;
Zohar, Sarah .
CLINICAL PHARMACOKINETICS, 2009, 48 (06) :387-395
[22]   Phase III clinical trials with darbepoetin: implications for clinicians [J].
Glaspy, J .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (03) :407-416
[23]   Optimal planning of phase II/III programs for clinical trials with multiple endpoints [J].
Kieser, Meinhard ;
Kirchner, Marietta ;
Doelger, Eva ;
Goette, Heiko .
PHARMACEUTICAL STATISTICS, 2018, 17 (05) :437-457
[24]   Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review [J].
Bregni, Giacomo ;
Trevisi, Elena ;
Conde, Rita Saude ;
Vanhooren, Michele ;
Telli, Tugba Akin ;
Assaf, Irene ;
Hendlisz, Alain ;
Di Maio, Massimo ;
Sclafani, Francesco .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (05) :505-513
[25]   Do investigators show selection biases when enrolling patients in phase I oncology registration trials? [J].
Yonemori, Kan ;
Hirakawa, Akihiro ;
Ando, Masashi ;
Hirata, Taizo ;
Shimizu, Chikako ;
Katsumata, Noriyuki ;
Tamura, Kenji ;
Fujiwara, Yasuhiro .
JOURNAL OF GERIATRIC ONCOLOGY, 2011, 2 (01) :25-30
[26]   Why performance status? A case for alternative functional assessments in pediatric oncology clinical trials [J].
Steineck, Angela ;
Rosenberg, Abby R. .
CANCER, 2021, 127 (19) :3511-3513
[27]   Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II? [J].
O'Donnell, Peter H. ;
Stadler, Walter M. .
CLINICAL CANCER RESEARCH, 2012, 18 (10) :2809-2816
[28]   Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review [J].
Palermos, Dionysios ;
Sergentanis, Theodoros N. ;
Gavriatopoulou, Maria ;
Malandrakis, Panagiotis ;
Psaltopoulou, Theodora ;
Terpos, Evangelos ;
Ntanasis-Stathopoulos, Ioannis .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)
[29]   Performance Status Restriction in Phase III Cancer Clinical Trials [J].
Jaoude, Joseph Abi ;
Kouzy, Ramez ;
Mainwaring, Walker ;
Lin, Timothy A. ;
Miller, Austin B. ;
Jethanandani, Amit ;
Espinoza, Andres F. ;
Pasalic, Dario ;
Verma, Vivek ;
VanderWalde, Noam A. ;
Smith, Benjamin D. ;
Smith, Grace L. ;
Fuller, C. David ;
Das, Prajnan ;
Minsky, Bruce D. ;
Roedel, Claus ;
Fokas, Emmanouil ;
Jagsi, Reshma ;
Thomas, Charles R., Jr. ;
Subbiah, Ishwaria M. ;
Taniguchi, Cullen M. ;
Ludmir, Ethan B. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (10) :1322-1326
[30]   Sample size estimation in phase III cancer clinical trials [J].
Curran, D ;
Sylvester, RJ ;
Boes, GH .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1999, 25 (03) :244-250